Citius Oncology (CTOR) Cash from Investing Activities (2023 - 2026)
Citius Oncology's (CTOR) quarterly Cash from Investing Activities came in at -$2.0 million in Q2 2026, down 233.33% quarter-over-quarter from -$600000.0 in Q1 2026.
Powered by 
Analysis
Citius Oncology (CTOR) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Cash from Investing Activities for 4 consecutive years, with -$2.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$2.0 million in Q2 2026; TTM through Jun 2026 was -$6.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$5.8 million, down 15.0% from the prior year.
- Cash from Investing Activities was -$2.0 million for Q2 2026 at Citius Oncology, down from -$600000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $24.7 million in Q1 2024 and troughed at -$4.4 million in Q4 2025.
- A 4-year average of $2.9 million and a median of -$630000.0 in 2023 frame the typical range for Cash from Investing Activities.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 281.26 Mn |
| 10 | Citius Oncology | 101.41 Mn | 101.41 Mn | 1.00 Mn | -2.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.00 Mn |
| Mar 31, 2026 | -600,000.00 |
| Dec 31, 2025 | -4.40 Mn |
| Jun 30, 2024 | 68,644.00 |
| Mar 31, 2024 | 24.74 Mn |
| Sep 30, 2023 | -660,000.00 |